Abstract A family history of prostate cancer (PCa) is an established risk factor for PCa. In case of a positive family history, the balance between positive and adverse effects of prostate-specific antigen (PSA) testing might be different from the general population, for which the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a beneficial effect on mortality. This, however, went at the cost of considerable overtreatment. This study assessed Dutch physicians' knowledge of heredity and PCa and their 'post-ERSPC' attitude towards PCa testing, including consideration of family history. In January 2010, all Dutch urologists and clinical geneticists (CGs) and 300 general practitioners (GPs) were invited by email to complete an anonymous online survey, which contained questions about hereditary PCa and their attitudes towards PCa case-finding and screening. 109 urologists (31%), 69 GPs (23%) and 46 CGs (31%) completed the survey. CGs had the most accurate knowledge of hereditary PCa. All but 1 CG mentioned at least one inherited trait with PCa, compared to only 25% of urologists and 9% of GPs. CGs hardly ever counseled men about PCa testing. Most urologists and GPs discuss possible risks and benefits before testing for PCa with PSA. Remarkably, 35-40% of them do not take family history into consideration. Knowledge of urologists and GPs about heredity and PCa is suboptimal. Hence, PCa counseling might not be optimal for men with a positive family history. Multidisciplinary guidelines on this topic should be developed to optimize personalized counseling.
Introduction
A positive family history of prostate cancer (PCa) is an established risk factor for PCa. First-degree relatives of affected men have a 2-3 fold increased risk of PCa [1] . When 3 or more first-degree relatives are affected (or at least 2 first-degree relatives before the age of 55 years), the family is considered a 'Hereditary Prostate Cancer' (HPC) family according to the so-called Johns Hopkins or Carter criteria [2] . An estimated 5-10% of PCa has a genetic cause. Yet, only a few very rare high-penetrance gene mutations have been identified to cause HPC [3] . In recent years, genome-wide association studies have added approximately 40 low-penetrance genetic polymorphisms that are associated with an increased risk of PCa [4, 5] . Several polymorphisms have also been identified that are associated with serum prostate-specific antigen (PSA), the most commonly used marker for early detection of PCa [6, 7] . An ongoing matter of debate is whether PSA testing should be used for population-wide screening [8] . In a population-based setting, the European Randomized Study of Screening for Prostate Cancer (ERSPC) showed a decrease in PCa mortality of 31% in the screening arm after correction for non-attendance and contamination. However, this mortality reduction coincided with considerable overtreatment [9, 10] . By contrast, the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO), found no effect of PSA screening on mortality [11] , but suffered from methodological problems which severely hamper interpretation of the results [12] .
Previous studies into the effectiveness of PSA sceening in men with an increased risk due to family history have yielded largely inconsistent results. These range from a marked benefit for men in high-risk PCa families (particularly for families with early onset PCas) to a decreased risk of PCa for non-affected men in HPC families [13, 14] . The increasing use of PSA testing in the general population has also had an important influence on men with a family history of PCa. Men with a positive family history are relatively more active in pursuing PSA testing than men in the general population. This has led to an increased detection of mainly of small localized tumors [15] .
To guide the public and physicians in translating the results of the ERSPC and PLCO into clinical practice, the Dutch Association of Urology (NVU) and the Dutch College of General Practitioners (NHG) concurrently released a policy statement in March 2009. This statement referred men to a website (http://www.prostaatwijzer.nl/) with information about PCa and PSA testing and advised them to consult their GP for further counseling [16] . It did, however, not discuss dealing with a family history of PCa or HPC. To date, in absence of official internationally accepted guidelines, the advice is to attempt to distinguish genetic predisposition-based families with multiple PCa cases from ascertainment-based multiple-case families and offer PCa screening only to the former [13] .
This study assessed the knowledge of Dutch urologists, general practitioners (GPs) and clinical geneticists (CGs) about HPC and PCa as a phenotype in hereditary syndromes. Furthermore, their 'post-ERSPC' attitude towards PCa testing and the role of family history in clinical decision-making about PCa testing were assessed. To our knowledge, this is the first study to investigate this in different professions that counsel men about PCa testing.
Materials and Methods
After publication of the results of the ERSPC and PLCO and the statements of the NVU and NHG, an online survey was developed [17] . This survey, targeted at Dutch urologists, GPs and CGs, contained questions about HPC and assessed the participants' general attitude towards PCa testing. In addition to this, it inquired into the role that family history played in the physician's daily clinical practice regarding PCa testing. The survey also included case descriptions of a man requesting to be tested for PCa. This fictitious man presented at different ages, in absence of family history and physical complaints. The survey could be completed anonymously.
In January 2010, all Dutch urologists (n = 351), clinical oncogeneticists (n = 32), CGs in training (n = 50) and genetic counselors (n = 68) were invited by e-mail from their respective professional associations. GPs in the region of the Comprehensive Cancer Centre East (CCCE) who were enlisted to receive the CCCE's e-newsletter (n = 300) were invited by e-mail.
For statistical analysis, descriptive analyses were performed, stratified by profession. Because of small numbers, clinical oncogeneticists, CGs in training and genetic counselors were pooled into one stratum (CGs). Chi-square testing was used to test for differences between professions. Participants who never counseled men about PCa testing were excluded from the analysis.
Results
In total, 225 surveys were completed (overall response rate 28%). These were submitted by 109 urologists (31%), 69 GPs (23%) and 46 CGs (31%). One pediatric urologist and two CGs were excluded from analyses because they never counseled men for PCa testing. Occasionally, participants did not complete all questions, causing small differences in the subtotals for different questions. Of the urologists, 66% (71/107) counseled men about PCa testing at least once a week and 93% (100/107) did this at least once a month.
In comparison, 85% of the GPs (59/69) did this at least once a month, as opposed to only 2% (1/44) of the CGs.
By contrast, the CGs had the most accurate knowledge of the HPC criteria: 72% (31/43) correctly selected the minimum of three affected first-degree relatives for the criterion that is most frequently fulfilled (Table 1) . In comparison, only 36% (38/105) of the urologists and 18% (12/66) of the GPs correctly selected this criterion (P \ 0.001). A majority of the GPs (59%) indicated not to know this definition. CGs were also best informed about the number of affected first-degree relatives with a PCa diagnosis before 55 years of age to meet the definition of HPC, although the differences between the groups were smaller. The third definition of HPC, i.e., three consecutive generations with PCa, was known to only a few participants.
Almost all CGs (41/42, 98%) listed at least one inherited trait with PCa as part of the phenotype, compared to only 24% (25/103) of the urologists and 9% (6/66) of the GPs.
The most frequently mentioned traits were the BRCA2 gene mutation (n = 60), the BRCA1 gene mutation (n = 40) and Lynch syndrome (n = 10). The rare HPC1, HPCX, MSR1, RNASEL and HPC2/ELAC2 mutations were sporadically mentioned.
Urologists had the least reservations towards PCa testing in a man with no physical complaints and no family history of PCa: 46% (32/69) of the GPs and 49% (22/45) of the CGs preferred to refrain from testing unless there were strong reasons to test (Table 2) , as compared to 31% (33/ 108) of the urologists. For a man presenting at 55 and 75 years of age, urologists and GPs gave similar answers. Between 70 and 80% of them would first inform him about the possible benefits and risks of PCa testing. CGs were more inclined not to test for PCa. At 45 years of age, more physicians in all groups would not test for PCa.
Age played a role when considering PCa testing. Of the urologists, 70% reported to use age limits, with 45 years as the mean and median lower age limit. This lower age limit was higher for GPs (60% reported age limits) and CGs (30% reported age limits), with 50 years of age being the median lower age limit. The median maximum age limit was 80 years (mean 77) for urologists and GPs, compared to 75 years (mean 74) for CGs. CGs always took family history into consideration when deciding whether or not to test for PCa. By contrast, 35-40% of urologists and GPs answered that family history would not influence the decision whether or not to test for PCa (Table 3 ). This did not vary between physicians with different general attitudes towards PSA testing (P = 0.47 for the urologists and P = 0.78 for the GPs), as was assessed in a previous question.
A majority of the urologists (76%) knew the ERSPC and PLCO results, compared to only 14 and 8% of CGs and GPs, respectively. Ninety-two percent (75/82) of the urologists who knew the studies found the ERSPC results more valuable. The statements of NVU and NHG, advising men to visit the website and consult the GP if further counseling was needed, were better known than the results of the trials: 85% (92/108) of the urologists and 59% (41/69) of the GPs was familiar with the statements. Of them, 12% (11/ 91) of the urologists and 24% (10/41) of the GPs did not agree with the statements. Only 2 of the 43 CGs (5%) were familiar with the statements.
Discussion
A positive family history of PCa is an important risk factor for PCa and the balance between pros and cons of PSA testing may be different in men with affected relatives. It is therefore remarkable that urologists and GPs are poorly informed about HPC. Only one in three urologists and one in five GPs is familiar with the criteria for HPC. Almost 60% of the GPs indicated not to know the definition. CGs were better informed, but they hardly ever counsel men about PCa testing. The BRCA1 gene mutation was frequently selected as an inherited trait with PCa as part of the phenotype. The evidence for an increased risk of PCa due to a BRCA1 gene mutation is quite weak, though. By contrast, for BRCA2 gene mutations (selected by 14 urologists and all 42 CGs) there is fairly solid evidence of familial clustering of aggressive PCa [18, 19] . Lynch syndrome was also selected 10 times, 7 times of which by urologists. Recently, an elevated risk of PCa for carriers of a mismatch-repair gene mutation was indeed found [20] . This has, however, not been confirmed in other studies, so it remains unclear whether the physicians who selected Lynch syndrome are correct. It should be noted that urologists and GPs hardly ever counsel patients with an elevated PCa risk based on these inherited traits.
In general, urologists reported the least reservations towards PCa testing and would test at a younger age than GPs and CGs. However, the majority of urologists and GPs stated to first discuss the risks and benefits of PSA testing and only test if a man would still want to be tested. So, even though 41% of GPs was not familiar with the statements regarding PCa testing and 92% of them did not know the ERSPC and PLCO results, they adhered just as well to the guidelines as the urologists. Participants who disagreed with the NVU/NHG statements, mostly indicated that the statements lacked attention for patients' preferences.
In contrast with the urologists and GPs, CGs would more often not test for PCa. This might be explained by the fact that the CGs mainly have an advisory role and refer their patients to a GP or urologist for PCa testing. CGs hardly ever counsel men about PCa testing, as there is no frequently occurring genetic defect known to cause PCa. This may change, however, when more data become available about the risk of PCa among BRCA2 carriers. An international study is currently examining this risk (www.impact-study.co.uk).
One of the most striking observations might be that more than one in three urologists and GPs would not take family history into account when deciding whether or not to test a man for PCa. Intuitively, one would think that men with a positive family history, and thus a higher a priori risk of PCa, would benefit more from PSA screening. Arguing against this is that HPC cases do not seem to differ from sporadic cases with respect to Gleason scores and PCa-specific survival [21, 22] . Even more so, screening programs amongst non-affected men in HPC families have shown that the chance of finding PCa in non-affected men in HPC families is low [13] . Although we did not address this in our study, when a man requesting PCa testing does have, e.g., an affected brother, he will very likely be tested, not in the least for reasons of anxiety management. However, whether this is beneficial, is doubtful. To better guide physicians in this matter, an addendum to PCa guidelines should be developed in a multidisciplinary collaborative effort, describing how to deal with PCa testing in case of a positive family history and HPC. The conclusion from a previous study to assess the extent and nature of the family history (predisposition-based vs. ascertainment-based) might well serve as a starting point for such a guideline [13] . In addition to this, the use of decision aids, e.g., the SWOP-PRI should be promoted [23] , as they already include the effect of family history in the risk estimates.
The results of this study should be interpreted with some caution. Although the responder groups were reasonably large in absolute numbers, the response rate was only 31% at best (for urologists and CGs). Hence, it is difficult to extrapolate the results to all Dutch physicians providing PCa counseling. Even more so, if physicians with more interest in this topic completed the survey more often, the results regarding knowledge about HPC and adherence to guidelines might be overoptimistic. On the other hand, intuitively physicians who take care of most of the counseling are most eager to complete the survey. It is also important to bear in mind that the results may not easily be extrapolated to other countries as they may be influenced by the health care system. In The Netherlands, e.g., men cannot visit a urologist without a referral from their GP.
In conclusion, the majority of urologists and GPs adhered to PCa testing guidelines. However, these guidelines do not include family history and many physicians indicated not to consider family history. Hence, PCa counseling might not be optimal for men with a positive family history. We propose that additional guidelines on this topic are developed in a multidisciplinary effort to optimize counseling.
